Introduction
Hepatitis C virus (HCV) infection affects an estimated 170 million individuals worldwide, and five million in the United States, where it is currently recognized as the most prevalent blood-borne infection and the leading indication for a liver transplant. 1, 2 Treatment of HCV with pegylated interferon (IFN)-a-2a is successful in eradicating the virus from only 30 to 80% of those treated, with individuals infected with the more resilient genotype-1 virus having markedly lower response rates than those with non-genotype-1 infections. 3, 4 In addition, differences in outcome have been described by race, with African Americans (AAs) having significantly lower response rates than Caucasian Americans (CAs). [5] [6] [7] Expressed in a number of different cell types, including hepatocytes, macrophages, B cells and T cells, interleukin-6 (IL-6) is a pleiotropic cytokine important in the immunological response to infections. IL-6 plays an important role in HCV infection, as well as the response to IFN therapy. In addition to interacting with crucial components of the IFN response pathways, IL-6 is an activator of acute phase proteins in hepatocytes. 8 A recent study has suggested the potential importance of IL-6 in the treatment response of HCV patients to IFN-based therapy. 9 Functional studies of IL-6 genetics suggest that its expression is complex. A number of single nucleotide polymorphisms (SNPs) have been described within the IL-6 gene that form conserved haplotypes. 10, 11 Although a number of these SNPs may have an impact on IL-6 expression, 10, 11 studies suggest that IL-6 regulation is complex, with haplotypes playing a critical role in IL-6 expression. 11 In this study, we examined whether host genetic diversity in the IL-6 gene is associated with the response to therapy for chronic HCV, with an emphasis on the role of IL-6 haplotypes. Table 1 presents the baseline demographics of the participants in this study. Briefly, slight differences in age were observed in the NIDDK (P ¼ 0.034, Wilcoxon rank-sum test) and the overall combined cohort by race (P ¼ 0.027, Wilcoxon rank-sum test), indicating that AAs are slightly older than CAs in our cohorts. In addition, slight differences in fibrosis score were observed in the NIDDK cohort by race (P ¼ 0.024, w 2 -test), indicating higher proportion of AAs exhibited a worse baseline fibrosis category (X3) than CAs. Whereas, the majority of AAs and CAs in Virahep-C cohort were in the milder fibrosis (o3) category. Nonetheless, we analyzed data by combining both cohort because of the small number of AA subjects in NIDDK cohort.
Results
Among AA participants, 86 (47.8%) had HCV genotype 1a infections, 81 (45.0%) genotype 1b infections and 13 (7.2%) a genotype-1 virus that could not be sub-genotyped or mixed 1a/1b infection. Among CA participants, 111 (57.2%) had HCV genotype 1a, 55 (28.4%) genotype 1b, and 28 (14.4%) a genotype-1 virus that could not be sub-genotyped or mixed 1a/1b infection. Participants in the NIDDK cohort were restricted to genotype 1-infected individuals.
Among the SNPs genotyped, rs13447445, rs13447446 and rs 2069829 were monomorphic and therefore not included in the analyses. Figure 1a summarizes the SNPs genotyped in this study and those included in haplotype construction. Figure 1b presents the 10-SNP haplotypes that occurred with a frequency 45% in each race and their respective associations with sustained viral response (SVR). The IL-6 T-T-G-G-G-G-C-A-G-A haplotype was associated with a lower risk of achieving SVR among CAs (relative risk (RR) ¼ 0.80; 95% CI: 0.66-0.98; P ¼ 0.0261). A similar trend was observed among AAs for this haplotype (RR ¼ 0.70; 95% CI: 0.44-1.13), but the association was not statistically significant (P ¼ 0.1275). Figure 2a presents the associations for the three-SNP sliding window analysis among AAs. None of the haplotypes tested were significantly associated with SVR. Figure 2b presents the associations for the three-SNP sliding window analysis among CAs. Frames containing SNP 4 (rs1800797), SNP 5 (rs1800796) and SNP 6 (rs1800795) had significant associations with SVR (sets 3, 4 and 5 in Figure 2b ). In particular, the rs1800797-(G)-rs1800796-(G)-rs1800795-(G) haplotype (set 4) was associated with a reduced chance of SVR (RR ¼ 0.79; 95% CI: 0.66-0.94; P ¼ 0.0081), as was the rs1800796-(G)-rs1800795-(G)-rs2069830-(C) haplotype (set 5) (RR ¼ 0.78; 95% CI: 0.66-0.94; P ¼ 0.0065).
The rs1800797-(G)-rs1800796-(G)-rs1800795-(G) haplotype (set 4) was independently associated with a reduced chance of SVR (RR ¼ 0.78; 95% CI: 0.62-1.0; P ¼ 0.0489) after adjustment for potential confounding factors, including race, baseline viral level, fibrosis score, gender and the interaction between race and baseline viral level ( Table 2) . Table 3 presents the associations for individual SNPs.
Discussion
Using a systematic analysis of IL-6 haplotypes, we observed consistent associations of haplotypes in this gene with a reduced likelihood of SVR. In particular, we observed the 10-SNP haplotype IL-6 T-T-G-G-G-G-C-A-G-A haplotype associated with a lower risk of achieving SVR among CAs (RR ¼ 0.80; 95% CI: 0.66-0.98; P ¼ 0.0261). Using a sliding window approach, we observed frames containing rs1800797, rs1800796 and rs1800795 to be associated with SVR. In particular, the rs1800797-(G)-rs1800796-(G)-rs1800795-(G) haplotype was associated with a reduced chance of SVR (RR ¼ 0.79; 95% CI: 0.66-0.94; P ¼ 0.0081), as was the rs1800796-(G)-rs1800795-(G)-rs2069830-(C) haplotype (RR ¼ 0.78; 95% CI: 0.66-0.94; P ¼ 0.0065). All associations were only observed among CAs. Our sliding window analyses further suggested that the region containing the SNPs rs1800797, rs1800796, rs1800795 and rs2069830 may be an important region in the IL-6 gene, with several haplotypes in this region associated with a lower likelihood of SVR. In vitro functional studies support the fact that this region may be of regulatory importance. 11, 12 Earlier studies of genetic variation in IL-6 and the response to HCV therapy have focused on SNPs. Natterman et al. 12 described an association between carriage of high-producing genotypes (that is, the GG or GC genotypes) 10 of the C-174G (rs1800795) polymorphism and a greater likelihood of SVR. In contrast, our haplotypic observations were of lowered likelihood of SVR. A functional study of IL-6 genetics by Terry et al., 11 suggests that IL-6 regulation is complex and that small differences on the haplotype level may have a significant impact on IL-6 expression. For example, they described a (À597G) þ (À572G) þ (À174G) clone containing a 9/11 base pair A n T n repeat to have greater levels of expression than one containing a 10/10 repeat. These observations reinforce the importance of haplotypes in IL-6 expression.
This study underscores the importance of examining genetic haplotypes in addition to individual SNPs. Our findings build on those of Nattermann et al. 12 collectively, both studies suggest that host genetic variation in the IL-6 gene may be important in the response to therapy for HCV. Additional studies are needed to fully elucidate the complex functional aspects of this gene.
Materials and methods

Study population and clinical data
This study utilized participants from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C), a National Institutes of Health (NIH)funded multicenter study aimed at understanding the mechanisms of resistance to antiviral therapy for chronic HCV infection among genotype-1-infected IFN treatment-naïve individuals. In addition, emphasis was placed on identifying factors that may contribute to differences in outcome by race among AAs and CAs. 5 All subjects were born in the United States and race was determined by a self-administered questionnaire.
We also utilized participants who were attending the NIH Clinical Center (N-113). Individuals who were treatment-naïve, infected with HCV genotype-1, and underwent IFN-based therapy (pegylated interferona þ ribavirin or IFN-a only) were included in this analysis. Available demographic data including selfreported race, sex, patient age and response to IFN were included in multivariable analyses.
Sustained virologic response was defined as having undetectable HCV-RNA 6 months after the discontinuation of therapy. The Roche Amplicor Assay version 2 with a lower limit of detection of 600 IU ml À1 was used in this study. Participants received a liver biopsy within 6 months before the start of therapy. Biopsies were scored by a single pathologist who was blinded to patient outcome using the Ishak modified histological activity index score. 13 To facilitate categorical analysis, biopsy scores were dichotomized as X3 and o3. All participants from both the Virahep-C study and the NIH clinical center provided written consent to participate in host genetics studies. Owing to the fact that several additional SNPs were genotyped in the NIDDK cohort and not in Virahep-C, only SNPs common to both cohorts were used for haplotype estimation. Note: the figure is not to scale. (b) Presents the haplotypes within each race with a frequency X5%, the observed frequencies, association with sustained viral response (SVR), the corresponding 95% CI (95% CI), and P-value for the association.
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Statistical analysis
Proportions of SVR by baseline demographic and clinical characteristics were compared using the two-sided raceadjusted Mantel-Haenszel w 2 -test. The non-parametric Wilcoxon rank-sum test was used to compare racial differences in distributions of continuous data (such as age, baseline viral level and proportion of peg-IFN). Unadjusted associations between individual haplotype (2N) and haplotype carrier (N) frequencies, as well as allele and allele carrier frequencies for examination of individual loci, with SVR were summarized using RR estimates, 95% CI (95% CI) and P-values.
Multiple Poisson regression models with sandwich estimators of the variance were utilized to adjust for potential confounding factors. 14 Potential confounding factors were selected based on the earlier published findings and data that were collected across both cohorts: included race, baseline viral levels, Ishak score and gender. 15 The SAS program, version 9 was used for all analyses. Statistical significance was set at a ¼ 0.05.
Genotyping
Among the 401 individuals treated in the Virahep-C Study, a subset of 373 consented to participate in host genetics studies and had DNA available for genotyping. Details of the Virahep-C host genetics ancillary study have been published earlier. 16 SNPs in the IL-6 gene were selected using the HapMap database. Initially, rs1880242, rs2056576, rs2069827 and rs2069845 were selected using HapMap version 1 and genotyped using the Illumina Figure 2 'Sliding window' analysis. Three-SNP sliding windows and the corresponding associations with sustained viralogic response (SVR) are presented. (a) Presents the results among African Americans (AAs), whereas (b) presents the results among Caucasian Americans (CAs). For each three-SNP block, the haplotype frequency, association with SVR (relative risk: (RR)), 95% CI interval and P-values are given. SNP 1 ¼ rs1880242; SNP 2 ¼ rs2056576; SNP 3 ¼ rs2069827; SNP 4 ¼ rs1800797; SNP 5 ¼ rs1800796; SNP 6 ¼ rs1800795; SNP 7 ¼ rs2069830; SNP 8 ¼ rs2069837; SNP 9 ¼ rs1554606; SNP 10 ¼ rs2069845. Only haplotypes with a frequency X5% are presented. Analyses were conducted using the Grasp program and SAS.
Beadarray system (Illumina Corporation, San Diego, CA, USA) for patients in both cohorts. In addition, rs2069860, rs13306435 and rs2069850 were genotyped using allelic discrimination in the NIDDK cohort, but not the Virahep-C study.
To increase the density of SNP coverage for the IL-6 gene, we further genotyped rs1554606, rs1800795, rs1800797, rs2069830 and rs2069837 by allelic discrimination using the ABI 7000 Sequence Detection System using TaqMan technology (Applied Biosystems, Foster City, CA, USA) for participants from both cohorts. In addition, genotyping for rs13447445, rs13447446, rs2069829 and rs1800796 was conducted using the fluorogenic 5 0 -nuclease TaqMan allelic discrimination assay on a 7900HT real time PCR instrument (Applied Biosystems) in both the cohorts. All probes and reagents were purchased from Applied Biosystems. All genotype calls were determined by two independent investigators, and only concordant calls were used.
Haplotype construction
We constructed haplotypes using the SAS Genetics module (SAS version 9.2) using a stepwise version of the EM algorithm (SAS version 9.1; Cary, NC, USA) separately by race. Owing to the nominal sample size of the NIDDK cohort (N ¼ 22 AAs and N ¼ 91 CAs), participants from both cohorts were combined for haplotype construction and to improve statistical power for analyses. As rs2069860, rs13306435 and rs2069850 were genotyped only in the NIDDK cohort and not the Virahep-C cohort, these SNPs were not included in haplotype construction to ensure that haplotypes Figure 2 Continued.
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were comparable across both cohorts. In addition, we conducted stratified analyses by cohort to determine whether the directions of associations are similar by cohort. We further evaluated linkage disequilibrium among genotyped loci by examining the pairwise linkage disequilibrium between each locus within each race using the SAS genetics module and the Grasp program. 17 Utilizing these data, we generated haplotypes consisting of three, four and five consecutive, overlapping SNPs. Using a 'sliding window' approach, we determined the association between carriage of smaller haplotype blocks and SVR by race to further refine specific regions of the IL-6 gene that may be contributing to the association with SVR. Only haplotypes with a frequency 45% within a race were analyzed for that race.
Evaluation of population structure
Using data from 161 ancestry-informative SNPs, we derived estimates of individual admixture for participants in the genetics study, and utilized the structured association method to evaluate the population structure. 16, 18, 19 We observed two distinct ancestral groups that had a strong correlation with self-reported race. 16 Consequently, we used self-reported race in these analyses.
